Overview

• UCLA and UC Davis will co-lead the PRISM trial with sites at Boston Medical Center, UC San Diego Health, Sylvester/University of Miami, University of Washington–Fred Hutch, and iversity of WiWisconsin–Madison across five states.
• Screening exams will be assigned to radiologist-only reads or to reads assisted by Transpara (ScreenPoint Medical) integrated via Aidoc’s aiOS, with radiologists retaining final decision authority.
• The study targets roughly 400,000 mammograms to measure changes in cancer detection and patient recall in routine U.S. practice.
• Researchers will also conduct surveys and focus groups to assess patient and clinician trust, usability, and perceptions of AI-assisted care.
• Findings are intended to inform clinical practice, insurance coverage, and technology adoption, with initial results expected no sooner than 2028.